Last updated: August 1, 2026
Idarubicin hydrochloride is an established generic anthracycline used mainly with cytarabine for induction therapy in adults with acute myeloid leukemia (AML). Its originator exclusivity has expired, no material U.S. patent barrier is expected, and commercial value is concentrated in hospital injectable supply rather than branded outpatient sales. Current clinical development is focused on combination regimens, AML subgroups and regional treatment protocols, not on a new idarubicin product franchise.
What is idarubicin hydrochloride used for?
Idarubicin hydrochloride is an intravenous anthracycline that inhibits topoisomerase II and intercalates into DNA. The FDA-approved indication is the treatment of adult AML in combination with other antileukemic agents, principally cytarabine [1].
The FDA label identifies idarubicin as a component of induction therapy for:
- Newly diagnosed adult AML.
- Combination regimens containing cytarabine.
- Post-remission or consolidation strategies at the treating physician’s discretion.
A commonly cited adult induction regimen is idarubicin 12 mg/m² intravenously daily for three days with cytarabine. Dosing varies by protocol, age, organ function, prior therapy and institutional practice [1].
Idarubicin is not interchangeable clinically with every anthracycline. Its use is constrained by cumulative cardiotoxicity, myelosuppression, mucositis, infection risk and anthracycline exposure limits.
How does idarubicin compare with daunorubicin?
| Factor |
Idarubicin hydrochloride |
Daunorubicin hydrochloride |
| Drug class |
Anthracycline |
Anthracycline |
| Primary hematologic use |
AML induction |
AML induction; broader historical use |
| Administration |
Intravenous |
Intravenous |
| Common AML combination |
Cytarabine |
Cytarabine |
| Generic availability |
Extensive |
Extensive |
| Main clinical constraint |
Cardiotoxicity and myelosuppression |
Cardiotoxicity and myelosuppression |
| Commercial position |
Mature hospital generic |
Mature hospital generic |
| Innovation status |
Combination and protocol optimization |
Combination and protocol optimization |
Comparative AML studies have reported activity for both idarubicin- and daunorubicin-based induction. Regimen choice depends on patient characteristics, institutional guidelines, dose intensity, toxicity management and competing agents such as venetoclax, midostaurin and gemtuzumab ozogamicin [2,3].
What is the current clinical-trial status of idarubicin hydrochloride?
Idarubicin has no major late-stage development program comparable to a novel AML therapy. Its clinical-trial activity is concentrated in investigator-sponsored studies and combination protocols.
Current and recent research themes include:
- Intensive AML induction. Idarubicin remains a comparator or backbone drug in studies evaluating induction intensity, cytarabine schedules and post-remission therapy.
- Venetoclax combinations. Modern AML trials increasingly compare intensive chemotherapy plus venetoclax against chemotherapy alone or against alternative anthracycline backbones.
- Older or medically fit adults. Trials assess whether idarubicin-containing intensive regimens can improve remission and measurable residual disease outcomes in selected older patients.
- Relapsed and refractory AML. Idarubicin may appear in salvage chemotherapy combinations, although its role is secondary to targeted agents, clinical trials and transplant-based treatment.
- Pediatric and adolescent AML. Idarubicin has been studied in pediatric chemotherapy protocols, but pediatric dosing and risk-benefit decisions remain protocol-specific.
- Regional treatment protocols. Studies in China, Europe and Latin America frequently evaluate idarubicin-containing combinations because the drug is widely available and comparatively inexpensive.
ClinicalTrials.gov records should be separated into studies actively testing idarubicin as an intervention and studies that list it only as a background regimen or comparator. The latter category is substantially larger and does not represent a new commercial indication [4].
What clinical endpoints matter for idarubicin trials?
The principal endpoints are:
- Complete remission rate.
- Complete remission with incomplete hematologic recovery.
- Measurable residual disease negativity.
- Event-free survival.
- Overall survival.
- Relapse incidence.
- Treatment-related mortality.
- Grade 3 or 4 cardiac, infectious and hematologic toxicities.
For a mature cytotoxic drug, a new indication would generally require evidence that the idarubicin-containing regimen improves outcomes against current AML standards, reduces toxicity, or addresses a defined molecular or clinical subgroup.
What is the FDA regulatory status of idarubicin hydrochloride?
Idarubicin hydrochloride is an FDA-approved prescription oncology drug. The reference product is Idamycin PFS, an intravenous formulation historically associated with Pharmacia/Pfizer. Generic idarubicin hydrochloride injection products are marketed by multiple manufacturers and are listed in FDA drug databases and the Orange Book [1,5].
Key FDA characteristics
| Regulatory item |
Status |
| Active ingredient |
Idarubicin hydrochloride |
| Dosage form |
Sterile intravenous injection |
| Therapeutic class |
Anthracycline antineoplastic |
| FDA indication |
Adult AML in combination with other antileukemic agents |
| Approval pathway for generics |
Abbreviated New Drug Application |
| Reference product |
Idamycin PFS |
| Biosimilar pathway |
Not applicable |
| Primary regulatory risk |
Manufacturing quality, sterility, supply continuity and labeling compliance |
Idarubicin is a small-molecule drug, so biosimilar approval does not apply. Generic competition proceeds through the ANDA pathway rather than the 351(k) biologics pathway.
What patents protect idarubicin hydrochloride?
The original composition-of-matter and product exclusivity for idarubicin hydrochloride have expired. The commercial product is now primarily protected, if at all, by manufacturing know-how, sterile injectable controls, supplier relationships and regulatory approvals rather than enforceable molecule patents.
Patent and exclusivity position
| Protection category |
Current commercial relevance |
| Original compound patent |
Expired |
| Original product patent |
Expired |
| FDA orphan exclusivity |
Expired or not commercially controlling |
| U.S. pediatric exclusivity |
No material current barrier |
| Formulation patents |
No widely recognized blocking U.S. formulation estate |
| Method-of-use patents |
No material blocking estate for standard AML use |
| Manufacturing patents |
Potentially relevant to individual processes, but not a broad market barrier |
| Orange Book patent barrier |
No material current barrier expected |
The Orange Book should be checked for the specific reference-listed drug and current listed patents because listings can change by product and applicant. For mature generic idarubicin, the practical expectation is that ANDA applicants do not face a meaningful Paragraph IV patent campaign comparable to protected oncology products [5].
When did idarubicin lose exclusivity?
Idarubicin lost meaningful U.S. market exclusivity decades ago. The original product was approved in the early 1990s, and generic competition has been available for many years. Any remaining commercial protection is product-specific and does not preserve molecule-level exclusivity.
What is the Paragraph IV risk for idarubicin?
Paragraph IV risk is low relative to newer oncology products. A generic applicant may still certify against any listed patent, but the litigation economics are limited because:
- The reference product is mature.
- Multiple generic suppliers already participate.
- Hospital purchasing is price-sensitive.
- The product has no meaningful branded premium.
- Market share can be won through supply reliability and contract pricing rather than patent exclusivity.
The main litigation risks are therefore more likely to involve manufacturing processes, product quality, labeling, supply contracts or regulatory enforcement than infringement of a commercially significant composition patent.
What formulations are protected by idarubicin patents?
The principal marketed presentation is a sterile intravenous formulation. Unlike newer oncology products, idarubicin has no commercially dominant extended-release, liposomal, oral or targeted-delivery formulation.
Formulation and manufacturing barriers
The most relevant technical barriers are operational:
- Sterile manufacturing validation.
- Control of particulate matter and endotoxins.
- Container-closure integrity.
- Stability of the finished injectable product.
- Control of anthracycline-related impurities and degradation products.
- Cold-chain or controlled-storage requirements where applicable.
- Availability of active pharmaceutical ingredient.
- Containment procedures for cytotoxic manufacturing.
These controls can limit the number of reliable suppliers even when patent protection is absent. The resulting barrier is regulatory and manufacturing-based, not exclusivity-based.
Which companies compete in the idarubicin hydrochloride market?
Competition is fragmented across generic injectable manufacturers and regional distributors. Depending on jurisdiction and product availability, suppliers may include Fresenius Kabi, Hikma, Teva, Accord Healthcare, Sun Pharmaceutical, Cipla, Dr. Reddy’s Laboratories and other regional oncology manufacturers.
Supplier presence varies by country, hospital tender and regulatory approval. The relevant competitive factors are:
- Product availability.
- Shortage history.
- Approved vial sizes.
- Hospital contract pricing.
- Manufacturing capacity.
- Regulatory inspection record.
- Distributor coverage.
- Ability to supply multiple oncology injectables.
The reference brand has limited strategic importance in most markets because clinicians and hospitals generally procure generic idarubicin through institutional channels.
What is the idarubicin hydrochloride market size?
Public market estimates for idarubicin alone are inconsistent because commercial databases often combine it with anthracyclines, AML medicines or generic oncology injectables. A precise global product revenue figure cannot be inferred from public FDA data.
The market has the following characteristics:
- Predominantly institutional and hospital-based.
- Low average selling price compared with targeted AML medicines.
- High dependence on generic tenders.
- Limited direct-to-consumer promotion.
- Modest unit growth tied to AML incidence and treatment intensity.
- Revenue pressure from generic competition.
- Substitution risk from daunorubicin, liposomal daunorubicin, venetoclax-based regimens and lower-intensity therapies.
A reasonable commercial model treats idarubicin as a mature, low-growth injectable rather than a growth oncology asset.
What is the 2030 market projection?
A scenario-based projection is more reliable than a single market-size estimate.
| Scenario through 2030 |
Volume trend |
Price trend |
Revenue outlook |
| Downside |
Decline of 2% to 4% annually |
Decline of 3% to 6% annually |
Annual revenue contraction of roughly 5% to 10% |
| Base case |
Flat to 2% annual growth |
Decline of 2% to 4% annually |
Flat to modest decline |
| Upside |
Growth of 2% to 4% annually |
Flat to decline of 1% to 2% annually |
Low-single-digit annual growth |
The base case assumes stable AML treatment volumes, continued use in intensive induction and ongoing generic price erosion. The upside case requires supply shortages affecting competing anthracyclines, increased use in emerging markets or protocol adoption that expands idarubicin-containing induction. The downside case reflects substitution by venetoclax-based regimens, lower-intensity treatment for older adults and further tender-price compression.
What revenue exposure do companies have to idarubicin?
Idarubicin is unlikely to be a material revenue driver for diversified pharmaceutical companies. Its financial value is greater for specialized generic manufacturers with:
- Existing sterile oncology capacity.
- Established hospital distribution.
- A broad injectable portfolio.
- Low-cost API access.
- Ability to maintain supply during shortages.
For large pharmaceutical companies, idarubicin is generally a portfolio-completion product. For smaller generic companies, it can provide recurring tender revenue but carries low pricing power and operational exposure to manufacturing interruptions.
The most material financial risk is not patent expiry. It is loss of supply, product discontinuation, failed inspections or inability to compete in hospital tenders.
What generic launch scenarios exist for idarubicin?
A new generic entrant would most likely pursue one of four strategies:
- Price-led tender entry. The applicant competes on vial price and accepts low margins.
- Supply-reliability strategy. The applicant targets hospitals concerned about shortages and maintains buffer inventory.
- Portfolio bundling. Idarubicin is offered with cytarabine, daunorubicin and other oncology injectables.
- Regional expansion. The supplier enters markets where generic competition is less dense or where AML treatment capacity is expanding.
A successful launch would require an approved injectable product, validated sterile production, stable API supply and hospital procurement access. Patent clearance alone would not ensure commercial success.
What patent litigation affects idarubicin hydrochloride?
No major current U.S. patent litigation is broadly associated with standard idarubicin hydrochloride injection. The drug’s litigation profile is materially less complex than that of newer AML products such as oral targeted therapies, IDH inhibitors, FLT3 inhibitors and venetoclax.
Potential disputes could arise from:
- ANDA patent certifications.
- Manufacturing-process claims.
- Trade-secret allegations.
- Product labeling.
- Sterility or quality issues.
- Distribution and supply agreements.
These risks are generally narrower than molecule-level patent litigation and are unlikely to delay generic entry across the market.
How strong is the idarubicin patent estate?
The patent estate is weak from a current commercial-exclusivity perspective. Its principal strengths are historical, not forward-looking.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Standard AML method protection |
Weak or expired |
| Formulation protection |
Limited |
| Manufacturing know-how |
Potentially relevant |
| Generic entry barrier |
Low |
| Litigation leverage |
Low |
| 2030 exclusivity value |
Minimal |
The strongest defensible assets associated with idarubicin are likely to be manufacturing quality systems, regulatory approvals and supply capability.
Key Takeaways
- Idarubicin hydrochloride is an FDA-approved generic anthracycline used mainly in adult AML induction.
- The drug is commonly administered with cytarabine in intensive chemotherapy.
- Clinical research focuses on combination regimens, AML subgroups and protocol optimization.
- No biosimilar pathway applies because idarubicin is a small molecule.
- Original composition and product exclusivity have expired.
- The current U.S. patent and Orange Book position presents no material molecule-level barrier to generic competition.
- Commercial value is concentrated in hospital injectable supply, tender access and manufacturing reliability.
- The base-case 2030 outlook is flat to modestly negative revenue growth because volume stability is offset by generic price erosion.
- The main risks are substitution by newer AML regimens, hospital tender pricing, shortages and sterile-manufacturing disruptions.
- Idarubicin is strategically more important as a portfolio product for injectable-generic manufacturers than as a standalone growth asset.
FAQs About Idarubicin Hydrochloride
Is idarubicin hydrochloride still used for AML induction?
Yes. It remains an accepted anthracycline component of intensive AML induction, generally in combination with cytarabine and selected according to patient fitness and treatment protocol.
Does idarubicin hydrochloride have an orphan-drug monopoly today?
No. Any historical orphan exclusivity does not create a current market-wide monopoly. Generic products are available in multiple jurisdictions.
Can a company launch generic idarubicin without a Paragraph IV challenge?
Where no relevant unexpired Orange Book patent is listed, an applicant may rely on a certification pathway other than Paragraph IV. The exact certification depends on the current listing for the reference product and the applicant’s legal position.
Is oral idarubicin commercially available?
The established U.S. product is an intravenous formulation. Oral or alternative delivery approaches have been studied in oncology research but do not define the current U.S. idarubicin market.
What could increase demand for idarubicin by 2030?
Demand could increase through AML incidence growth, expansion of intensive treatment in emerging markets, procurement shortages involving competing anthracyclines or broader adoption of idarubicin-containing protocols. These factors would likely support volume more than pricing.
References
- U.S. Food and Drug Administration. (2023). Idarubicin hydrochloride injection prescribing information. FDA/DailyMed.
- National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Acute myeloid leukemia.
- Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Löwenberg, B., Naoe, T., Sierra, J., Takahashi, H., Tien, H. F., Tomasson, M. H., Wei, A. H., & Bloomfield, C. D. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel. Blood, 140(12), 1345-1377.
- U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Idarubicin clinical studies.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
